Fig 2: Identification of AP heterodimers as molecular target of BG2. a) The binding of BG2, anti-IAP, and anti-PLAP to AP knock down LoVo cells, binding toward LoVo cells was assessed at 72 h after siRNA treatment. b,c) The binding of BG2, anti-IAP, and anti-PLAP to PLAP, GCAP, or IAP overexpressed PC-3 cells. d) Western blot assay of recombinant PLAP, GCAP, or IAP overexpressed on PC-3 cells. PC-3 cells were transfected with control plasmid (lane 1), IAP plasmid (lane 2), PLAP plasmid (lane 3), GCAP plasmid (lane 4), IAP + PLAP plasmids (lane 5), IAP + GCAP plasmids (lane 6), and PLAP + GCAP plasmids (lane 7). e) Western blot assay of AP dimers after in situ chemical crosslinking: lane 1, lysate of LoVo cells (uncrosslinked); lane 2, lysate of DSS crosslinked LoVo cells; lane 3, proteins pulled down by aptamer BG2 from lysate of DSS crosslinked LoVo cells.